<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cefotetan: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cefotetan: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cefotetan: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11318" href="/d/html/11318.html" rel="external">see "Cefotetan: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13130" href="/d/html/13130.html" rel="external">see "Cefotetan: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F46216290"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cefotan [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F147623"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Cephalosporin (Second Generation)</li></ul></div>
<div class="block doa drugH1Div" id="F147596"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b>
<b>IM, IV:</b> 1 to 2 g every 12 hours (maximum dose/day: IV: 6 g/day; IM: 4 g/day).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="19ad33d2-38a3-4047-a6e2-816347270335">Pelvic inflammatory disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pelvic inflammatory disease:</b>
<b>IV:</b> 2 g every 12 hours in combination with doxycycline. Total duration of therapy (which may include oral step-down therapy) is 14 days; oral therapy can usually be initiated within 24 to 48 hours of clinical improvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> 1 g every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 1 g every 12 hours or 2 g every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe: <b>IV:</b> 2 g every 12 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis:</b>
<b>IV:</b> 2 g within 60 minutes prior to surgery. Doses may be repeated in 6 hours if procedure is lengthy or if there is excessive blood loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection:</b>
<b>IM, IV:</b> 500 mg every 12 hours or 1 to 2 g every 12 to 24 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990427"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">IM, IV:</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Manufacturer’s labeling: </i>
<b>Note: </b> Renal function estimated using the Cockcroft-Gault formula:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 10 to 30 mL/minute: Administer usual dose every 24 hours <b>or</b> 50% of the usual dose administered every 12 hours</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: Administer usual dose every 48 hours <b>or</b> 25% of the usual dose administered every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease (ESRD) on intermittent hemodialysis: Dialyzable (5% to 20%); administer 25% the usual dose every 24 hours on days between dialysis; administer 50% the usual dose on the day of dialysis (administer after dialysis).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Alternate recommendations: </i>
<b>Note:</b> Renally adjusted dose recommendations are based on a dose of 1 to 2 g every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-4em;margin-left:6em;">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-4em;margin-left:6em;">GFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer every 24 hours.</p>
<p style="text-indent:-4em;margin-left:6em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer every 48 hours.</p>
<p style="text-indent:-4em;margin-left:6em;">Peritoneal dialysis: 1 g every 24 hours</p>
<p style="text-indent:-4em;margin-left:6em;">Continuous renal replacement therapy: Administer every 24 hours.</p></div>
<div class="block doha drugH1Div" id="F50987607"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F147597"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F147614"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13130" href="/d/html/13130.html" rel="external">see "Cefotetan: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, susceptible infection:</b> Infants, Children, and Adolescents: IM, IV: 30 to 50 mg/kg/dose every 12 hours; maximum dose: 3,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="485d58ca-9e0e-4284-8228-d55fd4f946ff">Intra-abdominal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection:</b> Limited data available: <b>Note:</b> Not recommended for empiric treatment due to high rates of resistant anaerobes, including <i>Bacteroides fragilis</i>, and potential for decreased efficacy.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 20 to 40 mg/kg/dose every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345','lexi-content-ref-28085573'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="19ad33d2-38a3-4047-a6e2-816347270335">Pelvic inflammatory disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pelvic inflammatory disease:</b> Limited data available: Children ≥45 kg and Adolescents: IV: 2,000 mg every 12 hours in combination with doxycycline for 14 days. Oral step-down therapy can usually be initiated within 24 to 48 hours of clinical improvement and may be used to complete 14-day treatment course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="37ebdac4-ff35-44d0-98a4-ce8a56c32a31">Peritonitis, prophylaxis for patients receiving peritoneal dialysis undergoing GI or genitourinary procedures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis, prophylaxis for patients receiving peritoneal dialysis undergoing GI or genitourinary procedures:</b> Limited data available: Infants, Children, and Adolescents: IV: 30 to 40 mg/kg administered 30 to 60 minutes before procedure; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis:</b> Limited data available: Children and Adolescents: IV: 40 mg/kg within 60 minutes prior to procedure; may repeat dose in 6 hours for prolonged procedure or excessive blood loss; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51084345"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: Dosage adjustments are not provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>). <b>Note:</b> Renally adjusted dose recommendations are based on doses of 20 to 40 mg/kg/dose every 12 hours:</p>
<p style="text-indent:-2em;margin-left:4em;">GFR ≥30 mL/minute/1.73 m<sup>2</sup>: No adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 20 to 40 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 20 to 40 mg/kg/dose every 48 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent hemodialysis: 20 to 40 mg/kg/dose every 48 hours; give after dialysis on dialysis days.</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis (PD): 20 to 40 mg/kg/dose every 48 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous renal replacement therapy (CRRT): 20 to 40 mg/kg/dose every 12 hours.</p></div>
<div class="block dohp drugH1Div" id="F51084346"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F147562"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (1%; including increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased lactate dehydrogenase</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia, positive direct Coombs’ test, thrombocythemia</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Discomfort at injection site, injection-site phlebitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i> colitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, hemolytic anemia (Martin 2006), leukopenia, prolonged prothrombin time (Williams 1991), thrombocytopenia (Christie 1988)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Jeon 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine, nephrotoxicity</p></div>
<div class="block coi drugH1Div" id="F147578"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;">Hypersensitivity to cefotetan, any component of the formulation, or other cephalosporins; previous cephalosporin-associated hemolytic anemia.</p></div>
<div class="block war drugH1Div" id="F147559"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Elevated INR: May be associated with increased INR and subsequent bleeding, especially in nutritionally deficient patients, prolonged treatment, or patients with cancer, hepatic or renal disease. Monitor coagulation parameters and manage as clinically indicated (eg, administration of phytonadione).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemolytic anemia: May rarely cause hemolytic anemia (including fatalities). Has been associated with a higher risk of hemolytic anemia relative to other cephalosporins (approximately threefold); monitor carefully during use and consider cephalosporin-associated immune anemia in patients who have received cefotetan within 2 to 3 weeks (either as treatment or prophylaxis). Discontinue drug, if applicable, and institute supportive measures as clinically indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, may occur. If an allergic reaction occurs, discontinue treatment and institute appropriate supportive measures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Penicillin allergy: Use with caution in patients with a history of penicillin allergy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• GI disease: Use with caution in patients with a history of GI disease, particularly colitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required.</p></div>
<div class="block foc drugH1Div" id="F147571"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cefotan: 2 g (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cefotan: 1 g (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea); 2 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea [DSC]); 2 g (1 ea [DSC])</p></div>
<div class="block geq drugH1Div" id="F147555"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323048"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (cefoTEtan Disodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $29.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g (per each): $58.13</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F147575"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IM: Inject deep IM into large muscle mass.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Inject via direct IV over 3 to 5 minutes. Infuse via intermittent infusion over 30 minutes.</p></div>
<div class="block admp drugH1Div" id="F52612382"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Inject deep IM into large muscle mass such as the upper outer quadrant of the gluteus maximus.</p>
<p style="text-indent:-2em;margin-left:2em;">IV intermittent: Infuse over 20 to 60 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">IV push: Inject over 3 to 5 minutes.</p></div>
<div class="block use drugH1Div" id="F147574"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bone and joint infection:</b> Treatment of bone and joint infection caused by<i> Staphylococcus aureus </i>(methicillin susceptible). <b>Note: </b>In the native vertebral osteomyelitis guidelines, cefotetan is not recommended for the treatment of staphylococcal infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gynecologic infection: </b>Treatment of gynecologic infection caused by <i>S. aureus </i>(methicillin susceptible), <i>Staphylococcus epidermidis </i>(methicillin susceptible), <i>Streptococcus</i> spp., <i>Streptococcus agalactiae, Escherichia coli, Proteus mirabilis, Neisseria gonorrhoeae, Bacteroides fragilis, Prevotella melaninogenica, Bacteroides vulgatus,</i>
<i>Fusobacterium</i> spp., and gram-positive anaerobic cocci (including <i>Peptococcus</i>
<i>niger</i> and <i>Peptostreptococcus</i> spp.).</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Cefotetan has no activity against <i>Chlamydia (Chlamydophila) trachomatis</i>. When treating pelvic inflammatory disease, add appropriate antichlamydial coverage.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Lower respiratory tract infection: </b>Treatment of lower respiratory tract infection caused by <i>Streptococcus pneumoniae, S. aureus</i> (methicillin susceptible), <i>Haemophilus influenzae</i>, <i>Klebsiella </i>spp. (including <i>K. pneumoniae</i>), <i>E. coli, P. mirabilis,</i> and <i>Serratia marcescens</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Sepsis/septic shock:</b> Treatment of confirmed or suspected sepsis, in combination with an aminoglycoside.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection: </b>Treatment of skin and skin structure infection due to <i>S. aureus</i> (methicillin susceptible), <i>S. epidermidis</i> (methicillin susceptible), <i>Streptococcus pyogenes</i>, <i>Streptococcus</i> spp., <i>E. coli, K. pneumoniae, P. niger, </i>and <i>Peptostreptococcus</i> spp.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis: </b> Preoperative administration in surgical procedures that are classified as clean contaminated or potentially contaminated (eg, cesarean section, abdominal or vaginal hysterectomy, transurethral surgery, biliary tract surgery, GI surgery).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection: </b>Treatment of urinary tract infection caused by <i>E. coli, Klebsiella</i> spp. (including <i>K. pneumoniae</i>), <i>P. mirabilis, Proteus vulgaris, Providencia rettgeri,</i> and <i>Morganella morganii.</i></p></div>
<div class="block mst drugH1Div" id="F147630"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CefoTEtan may be confused with ceFAZolin, cefOXitin, cefTAZidime, Ceftin, cefTRIAXone</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298991"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F147564"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CefoTEtan may enhance the adverse/toxic effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the nephrotoxic effect of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: Cephalosporins (N-methylthiotetrazole [NMTT] Side Chain Containing) may enhance the adverse/toxic effect of RifAMPin. Specifically, the risk for bleeding may be increased.  Management: Avoid concomitant use of rifampin with cephalosporins that contain an N-methylthiotetrazole (NMTT) side chain when possible. If combined, closely monitor prothrombin time or other coagulation tests and administer vitamin K as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F147589"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Concurrent use with ethanol may cause a disulfiram-like reaction. Management: Monitor patients.</p></div>
<div class="block pri drugH1Div" id="F6347590"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Cefotetan crosses the placenta and produces therapeutic concentrations in the amniotic fluid and cord serum. Cefotetan is one of the antibiotics recommended for prophylactic use prior to cesarean delivery.</p></div>
<div class="block brc drugH1Div" id="F147580"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Cefotetan is present in breast milk</p>
<p style="text-indent:-2em;margin-left:2em;">Although the manufacturer recommends to use with caution, cephalosporins are generally considered acceptable for use in breastfeeding women (Ito 2000). In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush or diarrhea (WHO 2002).</p></div>
<div class="block dic drugH1Div" id="F147581"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block mop drugH1Div" id="F147569"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor renal, hepatic, and hematologic function periodically with prolonged therapy. Monitor prothrombin time in patients at risk of prolongation during cephalosporin therapy (nutritionally-deficient, prolonged treatment, renal or hepatic disease). Monitor for signs and symptoms of hemolytic anemia, including hematologic parameters where appropriate.</p></div>
<div class="block pha drugH1Div" id="F147558"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F147577"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely to body tissues and fluids including bile, gallbladder, kidney, skin, tonsils, uterus, sputum, prostatic and peritoneal fluids.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 88%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: 1.85 to 3.5 hours (Martin 1994).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 3 to 4.6 hours, prolonged in patients with moderately impaired renal function (up to 10 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IM: 1 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (51% to 81%, as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F58130625"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Time dependent; associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC): Goal: ≥40% to 50% (<i>f</i>T) &gt; MIC (bacteriostatic), ≥60% to 70% (<i>f</i>T) &gt; MIC (bactericidal) (Abdul-Aziz 2020; Craig 1996; Craig 1998; Turnidge 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">Expected drug exposure in normal renal function:</p>
<p style="text-indent:-2em;margin-left:8em;">Adults, C<sub>max </sub>(peak):</p>
<p style="text-indent:-2em;margin-left:10em;">Single dose:</p>
<p style="text-indent:-2em;margin-left:12em;">500 mg: ~69 to 79 mg/L (Liu 2020; Yates 1983).</p>
<p style="text-indent:-2em;margin-left:12em;">1 g: ~126 to 142 mg/L (Liu 2020; Smith 1986; Yates 1983).</p>
<p style="text-indent:-2em;margin-left:12em;">2 g: ~237 to 337 mg/L (Carver 1989; Liu 2020; Yates 1983).</p>
<p style="text-indent:-2em;margin-left:10em;">Steady state: 1 g twice daily: 147.58 ± 22.71 mg/L (Liu 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect:</i> Generally &lt;1 hour; varies based on organism (Craig 1991; Craig 1998). For <i>Bacteroides</i> spp, highly variable ranging from 0 to 36 hours (Siverhus 1988).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038554"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apatef</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Apacef</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Apatef | Cepan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Yamatetan</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bc cefotetan | Cefoten | Cefotetan | Cetetan | Ckd Cefotetan | Kukje cefotetan na | Reyon cefotetan | Teram | Tetan kit | Unitetan | Urotetan | Yamatetan | Yungjin Sefotetan Sodium</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Apacef</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apatef</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cefotan | Cefotetan</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Apatef</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32383061">
<a name="32383061"></a>Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. <i>Intensive Care Med</i>. 2020;46(6):1127-1153. doi:10.1007/s00134-020-06050-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/32383061/pubmed" id="32383061" target="_blank">32383061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bailey.1">
<a name="Bailey.1"></a>Bailey K. Orbital cellulitis and abscess. In: Roy FH, Fraunfelder FW, Fraunfelder FT, eds. <i>Roy and Fraunfelder's Current Ocular Therapy</i>. 6th ed. Saunders; 2007:601.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26229122">
<a name="26229122"></a>Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46. doi:10.1093/cid/civ482<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/26229122/pubmed" id="26229122" target="_blank">26229122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. <i>Am J Health Syst Pharm</i>. 2013;70(3):195-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2745258">
<a name="2745258"></a>Carver PL, Nightingale CH, Quintiliani R. Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers<i>. J Antimicrob Chemother</i>. 1989;23(1):99-106. doi:10.1093/jac/23.1.99<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/2745258/pubmed" id="2745258" target="_blank">2745258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefotan.2">
<a name="Cefotan.2"></a>Cefotan (cefotetan) [prescribing information]. Buena, NJ: Teligent Pharma Inc; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefotan.1">
<a name="Cefotan.1"></a>Cefotan (cefotetan) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2004.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fresenius.1">
<a name="Fresenius.1"></a>Cefotetan [prescribing information]. Lake Zurich, IL: Fresenius Kabi; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Braun.1">
<a name="Braun.1"></a>Cefotetan and Dextrose (cefotetan for injection and dextrose for injection) [prescribing information]. Bethlehem, PA: B. Braun Medical Inc; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3219293">
<a name="3219293"></a>Christie DJ, Lennon SS, Drew RL, Swinehart CD. Cefotetan-induced immunologic thrombocytopenia. <i>Br J Haematol</i>. 1988;70(4):423-426. doi:10.1111/j.1365-2141.1988.tb02511.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/3219293/pubmed" id="3219293" target="_blank">3219293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craig.1">
<a name="Craig.1"></a>Craig WA. The postantibiotic effect. <i>Clinical Microbiology Newsletter</i>. 1991;13(16).</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8852915">
<a name="8852915"></a>Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. <i>Pediatr Infect Dis J</i>. 1996;15(3):255-259. doi:10.1097/00006454-199603000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/8852915/pubmed" id="8852915" target="_blank">8852915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9455502">
<a name="9455502"></a>Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. <i>Clin Infect Dis</i>. 1998;26(1):1-10; quiz 11-2. doi:10.1086/516284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/9455502/pubmed" id="9455502" target="_blank">9455502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3277054">
<a name="3277054"></a>Donowitz GR, Mandell GL. Beta-Lactam Antibiotics. <i>N Engl J Med</i>. 1988;318(7):419-426, 318(8):490-500.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/3277054/pubmed" id="3277054" target="_blank">3277054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118‐126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30212990">
<a name="30212990"></a>Jeon HJ, Ryu A, Min J, Kim NS. Maternal anaphylactic shock in pregnancy: a case report. <i>Medicine (Baltimore)</i>. 2018;97(37):e12351. doi:10.1097/MD.0000000000012351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/30212990/pubmed" id="30212990" target="_blank">30212990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32103903">
<a name="32103903"></a>Liu J, Zhai Y, Wu L, et al. Pharmacokinetics and tolerability of single and multiple intravenous doses of cefotetan disodium in healthy Chinese volunteers. <i>Drug Des Devel Ther</i>. 2020;14:613-620. doi:10.2147/DDDT.S234619<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/32103903/pubmed" id="32103903" target="_blank">32103903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10069359">
<a name="10069359"></a>Marshall WF, Blair JE. The Cephalosporins. <i>Mayo Clin Proc</i>. 1999;74(2):187-195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/10069359/pubmed" id="10069359" target="_blank">10069359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8013159">
<a name="8013159"></a>Martin C, Thomachot L, Albanese J. Clinical Pharmacokinetics of Cefotetan. <i>Clin Pharmacokinet</i>. 1994;26(4):248-258. doi:10.2165/00003088-199426040-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/8013159/pubmed" id="8013159" target="_blank">8013159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16493619">
<a name="16493619"></a>Martin ME, Laber DA. Cefotetan-induced hemolytic anemia after perioperative prophylaxis. <i>Am J Hematol</i>. 2006;81(3):186-188. doi:10.1002/ajh.20459<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/16493619/pubmed" id="16493619" target="_blank">16493619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25147175">
<a name="25147175"></a>Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. <i>Am J Health Syst Pharm</i>. 2014;71(17):1500-1508. doi:10.2146/ajhp140024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/25147175/pubmed" id="25147175" target="_blank">25147175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2948542">
<a name="2948542"></a>Quayle AA, Russell C, Hearn B. Organisms Isolated from Severe Odontogenic Soft Tissue Infections: Their Sensitivities to Cefotetan and Seven Other Antibiotics, and Implications for Therapy and Prophylaxis. <i>Br J Oral Maxillofac Surg</i>. 1987;25(1):34-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/2948542/pubmed" id="2948542" target="_blank">2948542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3165611">
<a name="3165611"></a>Siverhus DJ, Edmiston CE Jr, Clausz JC, Goheen MP. Post-antibiotic effect in Bacteroides fragilis group. <i>Ann Clin Lab Sci</i>. 1988;18(4):326-336.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/3165611/pubmed" id="3165611" target="_blank">3165611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3460524">
<a name="3460524"></a>Smith BR, LeFrock JL, Thyrum PT, et al. Cefotetan pharmacokinetics in volunteers with various degrees of renal function. <i>Antimicrob Agents Chemother</i>. 1986;29(5):887-893. doi:10.1128/AAC.29.5.887<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/3460524/pubmed" id="3460524" target="_blank">3460524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2010;50(2):133-164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9675443">
<a name="9675443"></a>Turnidge JD. The pharmacodynamics of beta-lactams. <i>Clin Infect Dis</i>. 1998;27(1):10-22. doi:10.1086/514622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/9675443/pubmed" id="9675443" target="_blank">9675443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;(32)(suppl 2):S32-S86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1918399">
<a name="1918399"></a>Williams KJ, Bax RP, Brown H, Machin SJ. Antibiotic treatment and associated prolonged prothrombin time. <i>J Clin Pathol</i>. 1991;44(9):738-741. doi:10.1136/jcp.44.9.738<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/1918399/pubmed" id="1918399" target="_blank">1918399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26042815">
<a name="26042815"></a>Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/26042815/pubmed" id="26042815" target="_blank">26042815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6573315">
<a name="6573315"></a>Yates RA, Adam HK, Donnelly RJ, Houghton HL, Charlesworth EA, Laws EA. Pharmacokinetics and tolerance of single intravenous doses of cefotetan disodium in male Caucasian volunteers. <i>J Antimicrob Chemother</i>. 1983;11 suppl:185-191. doi:10.1093/jac/11.suppl_a.185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefotetan-drug-information/abstract-text/6573315/pubmed" id="6573315" target="_blank">6573315</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9222 Version 214.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
